FINWIRES · TerminalLIVE
FINWIRES

Coca-Cola Plans Public Listing of Indian Bottling Unit in 2027

By

Global beverage giant, The Coca-Cola Company, plans to list Hindustan Coca-Cola Holdings, the parent company of the largest Coca-Cola bottler in India, Hindustan Coca-Cola Beverages, according to an official statement on Monday.

The India listing will include the sale of a portion of the Coca-Cola Company's shareholding in Hindustan Coca-Cola Holdings.

The company is working on a potential listing on the Bombay Stock Exchange and National Stock Exchange of India in 2027, subject to market conditions and applicable regulatory and other approvals.

In 2025, Indian conglomerate ​Jubilant Bhartia Group purchased a 40% stake in Hindustan Coca-Cola Holdings.

"The Coca-Cola Company will stay invested in this important bottler and focus on growing our portfolio of global and local brands in India," said Sanket Ray, president, India and Southwest Asia and Emerging Large Markets Lead for The Coca-Cola Company.

Hindustan Coca-Cola Beverages operates 14 bottling plants across 10 states in India and works with eight co-packers.

Related Articles

Asia

Telix Pharmaceuticals Says Prostate Cancer Treatement Candidate Shows Acceptable Tolerability in Phase Three Trial

Telix Pharmaceuticals (ASX:TLX) said its lutetium radio antibody-drug conjugate candidate, TLX591-Tx, demonstrated acceptable tolerability across all standard-of-care combination groups in the ProstACT global phase three study, with no new safety signals, supporting the feasibility of TLX591-Tx in combination with standard-of-care in post-ARPI metastatic castration-resistant prostate cancer, according to a Tuesday statement.The primary endpoint was the safety and tolerability of TLX591-Tx in combination with standard-of-care, while secondary endpoints included pharmacokinetics and radiation dosimetry.The trial enrolled prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer patients previously treated with one androgen receptor pathway inhibitor. It consisted of TLX591-Tx, administered as two doses 14 days apart, in combination with standard-of-care, which includes abiraterone, enzalutamide, or docetaxel, in comparison with standard-of-care alone. 36 patients received both doses of TLX591-Tx per protocol.Treatment-emergent non-hematologic events were primarily fatigue, nausea, and dry mouth. Radiation exposure to key organs was below established safety limits. Lesion dosimetry confirmed uptake across tumor sites and across all cohorts, while pharmacokinetics demonstrated sustained activity at Day 15.The firm initiated the second part of the study, a randomized treatment expansion, where it obtained regulatory approvals. It is engaging with the US Food and Drug Administration (FDA) to discuss the data from the first part and seek an Investigational New Drug (IND) amendment to advance the second part in the US.

$ASX:TLX
Asia

Air New Zealand Group Capacity Rises in April

Air New Zealand (NZE:AIR, ASX:AIZ) group capacity rose 2.4% year on year in April, according to a Tuesday filing with the Australian and New Zealand bourses.Long-haul available seat kilometers (ASKs) rose 0.3%, while domestic ASKs increased by 2.2%, per the filing.Short-haul international ASKs rose 6.9% year on year, supported by the addition of two new A321 aircraft.Group year-to-date underlying revenue per available seat kilometer rose 2.8% from the prior year.The airline carried 1.3 million passengers in April, up 2.2% from the previous year, while the passenger load factor rose to nearly 86%, up from around 84%, the filing added.The company's New Zealand shares were down 2% in recent Tuesday trade.

$ASX:AIZ$NZE:AIR
Asia

Market Chatter: Japan, US to Jointly Invest $1 Billion in AI, Advanced Tech Under Genesis Mission

Japan and the United States will jointly invest $1 billion over five years in artificial intelligence and other advanced fields under the Trump administration's Genesis Mission, Nikkei Asia reported Monday.Launched in 2025, the Genesis Mission aims to build a new AI platform by integrating federal scientific databases and national laboratory supercomputers. The project accelerates scientific research by using AI-driven hypothesis testing and automated processes.Under the agreement, Japan will contribute $500 million to collaborate on priority areas including biotechnology, nuclear fusion, and quantum information science, while senior Japanese officials plan to visit the US in early June for a joint announcement with the Department of Energy, the newswire said.Major tech companies, including Microsoft, Google, and Nvidia, will also participate by supplying advanced AI models and expanding supercomputing capacity, the report added.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^N225